Comparing Two Surgical Methods for Gastric Outlet Obstruction in Advanced Stage IV Gastric Cancer to Improve Recovery and Quality of Life
Led by Gyeongsang National University Hospital · Updated on 2026-08-11
144
Participants Needed
1
Research Sites
104 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are investigating whether stomach-partitioning gastrojejunostomy SPGJ is more effective than conventional gastrojejunostomy CGJ at reducing delayed gastric emptying after surgery in adults with unresectable stage IV gastric cancer causing malignant gastric outlet obstruction MGOO. This multicenter randomized trial aims to establish a new surgical standard to improve recovery and quality of life for patients with advanced gastric cancer.
Participants will be randomly assigned to one of two surgical groups the CGJ group will receive a standard laparoscopic gastrojejunostomy without partitioning, while the SPGJ group will undergo laparoscopic transverse gastric partitioning near the tumor followed by gastrojejunostomy. All surgeries follow standardized protocols and training across multiple hospitals. The trial includes a preparation phase, enrollment lasting one year, and one year of follow-up.
During the study, participants will be monitored for postoperative gastric emptying, time to oral food tolerance, hospital length of stay, complications, and survival outcomes. Data collection includes nutrition recovery, complication severity, and quality of life assessments. The primary outcome is delayed gastric emptying within 30 days after surgery. Secondary outcomes include oral tolerance day, hospital stay length, complication rates, obstruction recurrence, survival at 6 and 12 months, and quality of life. The trial duration is approximately three years from preparation to data analysis.
CONDITIONS
Brief Title
Malignant Gastric Outlet Obstruction Study With Stomach Partitioning (GO-PART)
Research Team
S
Sang-Ho Jeong, MD, PhD
J
Ji-Ho Park, MD, PhD
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match. Sign up to get personalized trial recommendations delivered to your inbox.
Histologically confirmed gastric adenocarcinoma with unresectable gastric outlet obstruction
Tumor located in the lower one-third of the stomach
Age between 20 and 85 years
ECOG Performance Status of 2 or less
ASA score Class I to III
Endoscopic or radiologic evidence of obstructive gastric outlet obstruction
You will not qualify if you...
Bowel obstruction caused by extensive peritoneal metastasis (P3)
Tumor extending beyond the lower one-third into the middle one-third of the stomach
Need for emergency surgery due to perforation or hemorrhage
Severe malnutrition with serum albumin less than 2.5 g/L
Currently undergoing pre-operative chemotherapy
Your Study Journey
Screening
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
Treatment
Duration - Up to 1 year enrollment period
Participants undergo either the conventional laparoscopic gastrojejunostomy or the stomach-partitioning gastrojejunostomy surgery.
Surgery performed once; follow-up assessments during hospitalization and post-discharge
Follow-up
Duration - 1 year
Participants are monitored for recovery, including delayed gastric emptying, oral food tolerance, complications, and survival outcomes for one year after surgery.
Regular follow-up visits during the year
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Similar Trials
Evaluating LY4257496 Radioligand Therapy in Adults With GRPR-Positive Advanced Solid Tumors Including Breast, Colorectal, and Prostate Cancer
Dose Escalation and Optimization of LY4337713 Radioligand Therapy for Adults with FAP-Positive Solid Tumors
Phase 1 Study of PF-08046050 SGN-CEACAM5C in Adults With Advanced or Metastatic Solid Tumors Not Responsive to Standard Treatments
Phase 1 Study Evaluating Sigvotatug Vedotin Alone and with Pembrolizumab, With or Without Chemotherapy, in Adults With Advanced Solid Tumors
Randomized Phase 2 Study of Adebrelimab with Famitinib and Irinotecan Versus Irinotecan Alone
in Adults With Advanced Gastric or Gastroesophageal Junction Cancer After First-Line Treatment Failure
Phase 1 Dose Escalation and Expansion Study of TNhYP218 CAR T Cells for Mesothelin-Expressing Solid Tumors Including Mesothelioma
Comparing Argon Plasma Coagulation and Endoscopic Mucosal Resection
for Treating Small Gastric Adenomas with Low-Grade Dysplasia
Comparing Endoscopic Biopsy to Surgery Samples for Molecular Testing in Gastric Cancer
Evaluating Reliability of Biopsy for Diagnosing Gastric Adenocarcinoma
Randomized Phase II Study of Conversion Therapy With Surgery and Radiotherapy Versus Standard Systemic Therapy for Para-Aortic Nodal Metastases in Gastric Adenocarcinoma
Blood Test Using High-Sensitivity Genetic Analysis for Early Detection and Monitoring of Multiple Cancers
Have more questions? Get in touch with our team for quick support
Published Research Related To This Trial
Stomach-partitioning versus conventional gastrojejunostomy for unresectable gastric cancer with gastric outlet obstruction: A propensity score matched cohort study.